Bartlett & CO. Wealth Management LLC Has $220,000 Stock Holdings in Solventum Co. (NYSE:SOLV)

Bartlett & CO. Wealth Management LLC cut its holdings in Solventum Co. (NYSE:SOLV) by 10.2% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 3,327 shares of the company’s stock after selling 378 shares during the quarter. Bartlett & CO. Wealth Management LLC’s holdings in Solventum were worth $220,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. Copeland Capital Management LLC acquired a new position in shares of Solventum in the 3rd quarter valued at approximately $26,000. Modus Advisors LLC acquired a new position in Solventum during the 4th quarter worth approximately $25,000. Mather Group LLC. acquired a new position in Solventum during the 3rd quarter worth approximately $27,000. True Wealth Design LLC boosted its position in Solventum by 23,550.0% during the 3rd quarter. True Wealth Design LLC now owns 473 shares of the company’s stock worth $33,000 after acquiring an additional 471 shares during the last quarter. Finally, Prospera Private Wealth LLC acquired a new position in Solventum during the 3rd quarter worth approximately $35,000.

Solventum Stock Performance

NYSE SOLV opened at $74.93 on Friday. Solventum Co. has a 12 month low of $47.16 and a 12 month high of $96.05. The stock has a 50 day moving average of $69.41 and a 200-day moving average of $66.13. The company has a debt-to-equity ratio of 2.45, a current ratio of 1.15 and a quick ratio of 0.83.

Solventum (NYSE:SOLV) last posted its quarterly earnings results on Thursday, November 7th. The company reported $1.15 earnings per share for the quarter, missing analysts’ consensus estimates of $1.38 by ($0.23). The company had revenue of $2.08 billion during the quarter, compared to analyst estimates of $2.05 billion. As a group, equities analysts expect that Solventum Co. will post 6.58 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on SOLV shares. Mizuho started coverage on Solventum in a research report on Wednesday, December 4th. They set a “neutral” rating and a $70.00 price target for the company. Morgan Stanley upped their price target on Solventum from $60.00 to $73.00 and gave the stock an “equal weight” rating in a research report on Monday, November 11th. Piper Sandler upped their price target on Solventum from $71.00 to $75.00 and gave the stock a “neutral” rating in a research report on Friday, November 8th. Finally, Stifel Nicolaus began coverage on Solventum in a report on Tuesday, October 8th. They issued a “buy” rating and a $82.00 price objective for the company. One research analyst has rated the stock with a sell rating, nine have given a hold rating and one has assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $68.29.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.